Journal article
Neuroprotection in emerging psychotic disorders
G Berger, M Dell'Olio, P Amminger, B Cornblatt, L Phillips, A Yung, Y Yan, M Berk, P McGorry
Early Intervention in Psychiatry | Published : 2007
Abstract
Aim: The emerging phase of psychotic disorders is pleomorphic and fluctuates in presentation. Hence, from a clinical perspective, treatment modalities are often unclear. This paper investigates the rational and potential use of neuroprotective agents in emerging psychotic disorders. Methods: Medline databases were searched from 1966 to 2006 followed by the cross-checking of references using following keywords: neuroprotection, apoptosis, natural cell death, neurodevelopment, plasticity, neurogenesis, combined with brain and schizophrenia. Results: Agents such as atypical antipsychotics, antidepressants, omega-3 fatty acids, modulators of glutamateric neurotransmission (e.g. ampakines, glycin..
View full abstractGrants
Funding Acknowledgements
Dr Gregor Berger was supported by the Swiss National Science Foundation, the Margaret and Walter Lichtenstein Foundation (University of Basel), the National Health and Medical Research Council of Australia, and the Colonial Foundation, Melbourne, Australia. Dr Berger has served as a consultant to, received honoraria from, and served as speaker at educational meetings for AstraZeneca, Eli Lilly and JanssenCilag.